TriPRIL CAR T Cells in Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMarcela V. Maus, M.D.,Ph.D.
About this trial
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.
This research study involves the study drugs:.
* TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Eligibility criteria
Qualifiers
Ability to understand and the willingness to sign a written informed consent document.
Age ≥18 years at the time of signing informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Life expectancy of greater than 12 weeks
Disqualifiers
Any prior systemic treatment for multiple myeloma within the 14 days prior to scheduled leukapheresis unless discussed with the medical monitor
Receiving high-dose (e.g., >10 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to leukapheresis
Autologous stem cell transplantation within 3 months prior to leukapheresis
Any prior allogeneic stem cell transplantation
Trial design
Treatments tested in this trial
- TriPRIL CAR T Cells
- Cyclophosphamide
- Fludarabine
Treatment groups
18 Participants
are divided into 2 treatment groupsSponsors and collaborators
Marcela V. Maus, M.D.,Ph.D.
Lead sponsor
Massachusetts General Hospital
Sponsor institution
Source ClinicalTrials.gov